Special Issue "Antiprotozoal Marine Natural Products"

Quicklinks

A special issue of Marine Drugs (ISSN 1660-3397).

Deadline for manuscript submissions: closed (15 August 2013)

Special Issue Editor

Guest Editor
Prof. Dr. Deniz Tasdemir
National University of Ireland, Galway, School of Chemistry, University Road, Galway, Ireland
E-Mail: deniz.tasdemir@nuigalway.ie
Phone: +353 91 492450
Fax: +353 91 495576
Interests: marine natural product chemistry; sponge; seaweed; cyanobacteria; deep sea organisms; structure elucidation; bioactivity; cancer; infectious diseases (malaria; tuberculosis; bacteria; HIV); fatty acid biosynthesis

Special Issue Information

Dear Colleagues,

Protozoa are a large group of unicellular eukaryotic organisms. Some protozoans are parasitic and when transmitted to human (generally via an insect vector) cause serious infectious diseases, such as malaria, sleeping sickness, Chagas’ disease, toxoplasmosis. Many of these diseases are ancient, but still pose a significant threat to global health, particularly to those populations living in tropical and subtropical areas of the world. In the absence of vaccines, the control of the protozoans has relied on chemotherapy. Natural products play a key role in the eradication of protozoal infections, particularly in malaria where almost all antimalarial drugs can be traced to a natural product scaffold. Despite the short history, marine resources have also proven to be an excellent source for antiprotozoal lead compounds, such as manzamines, plakortins and sesquiterpenoids with isonitrile function, to name a few.

This special issue dedicated to “Antiprotozoal Marine Natural Products” aims to emphasize the importance of novel approaches; discovery of new or understudied sources and novel molecules from marine flora and fauna to tackle these diseases. Marine microorganisms are also included, as in some cases, they are the true source of antiparasitic compounds.

As the Guest Editor, I encourage all scientists to submit their latest research findings in this area. I hope that it will contribute to future drug discovery efforts on protozoal infections, many of which are still placed under the category of ‘neglected diseases’.

Prof. Dr. Deniz Tasdemir
Guest Editor

Submission

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. Papers will be published continuously (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are refereed through a peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Marine Drugs is an international peer-reviewed Open Access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 1800 CHF (Swiss Francs).

Keywords

  • marine natural product
  • marine invertebrate
  • marine microorganism
  • marine alga
  • antiprotozoal marine natural product
  • protozoal infection
  • malaria
  • sleeping sickness
  • Chagas’ disease
  • leishmaniasis
  • Toxoplasmosis
  • giardiasis
  • drug discovery

Published Papers (7 papers)

Mar. Drugs 2014, 12(3), 1169-1184; doi:10.3390/md12031169
Received: 5 November 2013; in revised form: 22 January 2014 / Accepted: 30 January 2014 / Published: 4 March 2014
Show/Hide Abstract | Download PDF Full-text (1629 KB) | View HTML Full-text
abstract graphic

Mar. Drugs 2013, 11(12), 5036-5050; doi:10.3390/md11125036
Received: 12 September 2013; in revised form: 27 November 2013 / Accepted: 28 November 2013 / Published: 12 December 2013
Show/Hide Abstract | Download PDF Full-text (583 KB) | View HTML Full-text | Download XML Full-text |  Supplementary Files

Mar. Drugs 2013, 11(10), 4058-4082; doi:10.3390/md11104058
Received: 16 August 2013; in revised form: 9 October 2013 / Accepted: 10 October 2013 / Published: 22 October 2013
Show/Hide Abstract | Download PDF Full-text (1043 KB) | View HTML Full-text | Download XML Full-text

Mar. Drugs 2013, 11(10), 4019-4034; doi:10.3390/md11104019
Received: 13 August 2013; in revised form: 8 October 2013 / Accepted: 11 October 2013 / Published: 22 October 2013
Show/Hide Abstract | Download PDF Full-text (749 KB) | View HTML Full-text | Download XML Full-text
abstract graphic

Mar. Drugs 2013, 11(10), 3661-3675; doi:10.3390/md11103661
Received: 7 August 2013; in revised form: 1 September 2013 / Accepted: 10 September 2013 / Published: 30 September 2013
Show/Hide Abstract | Download PDF Full-text (413 KB) | View HTML Full-text | Download XML Full-text |  Supplementary Files
abstract graphic

Mar. Drugs 2013, 11(9), 3472-3499; doi:10.3390/md11093472
Received: 12 August 2013; in revised form: 20 August 2013 / Accepted: 30 August 2013 / Published: 9 September 2013
Show/Hide Abstract | Download PDF Full-text (797 KB) | View HTML Full-text | Download XML Full-text |  Supplementary Files
abstract graphic

Mar. Drugs 2013, 11(9), 3297-3308; doi:10.3390/md11093297
Received: 31 July 2013; in revised form: 16 August 2013 / Accepted: 19 August 2013 / Published: 28 August 2013
Show/Hide Abstract | Download PDF Full-text (405 KB) | View HTML Full-text | Download XML Full-text |  Supplementary Files
abstract graphic

Last update: 7 May 2013

Mar. Drugs EISSN 1660-3397 Published by MDPI AG, Basel, Switzerland RSS E-Mail Table of Contents Alert